№ files_lp_3_process_7_018550
File format: docx
Character count: 7211
File size: 17 KB
The document explains the immune system and its response to pathogens, detailing innate and adaptive immunity mechanisms, symptoms of infections, and the role of B and T cells in fighting diseases.
Year:
2017
Region / City:
N/A
Theme:
Immune System, Pathogens, Immunity
Document Type:
Educational Chapter
Organization / Institution:
McGraw-Hill
Author:
McGraw-Hill Biology
Target Audience:
Students, General Public
Duration:
N/A
Approval Date:
N/A
Modification Date:
N/A
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2022
Region / City:
United Kingdom
Theme:
Education, Teacher Salaries
Document Type:
Government Response
Organization:
Department for Education
Author:
James Cleverly
Target Audience:
Educators, Policy Makers, Government Officials
Period of Action:
2022/23 – 2023/24
Approval Date:
19 July 2022
Date of Amendments:
23 September 2022
Year:
1968
Region / City:
United Kingdom
Topic:
Vaccination, Measles, Immunology
Document Type:
Educational Text
Organization / Institution:
Not specified
Author:
Not specified
Target Audience:
Students, Health professionals
Effective Period:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Liverpool
Topic:
Paediatric Health, Medical Conditions
Document Type:
Information Leaflet
Author:
Unknown
Target Audience:
Parents and carers of children diagnosed with ITP
Period of Validity:
Until February 2028
Approval Date:
Unknown
Review Date:
February 2028
Year:
Not specified
Region / City:
Not specified
Theme:
Immunology
Document Type:
Research Project Description
Institution:
Nanyang Technological University (NTU)
Author:
Asst Prof Loh Jia Tong
Target Audience:
Not specified
Duration:
Not specified
Approval Date:
Not specified
Amendment Date:
Not specified
Year:
2021
Region / city:
Canada
Topic:
Rh Immunization Prevention
Document Type:
Guidelines
Organization / Institution:
CSTM
Author:
Not specified
Target audience:
Healthcare professionals (Physicians, Midwives, Technologists)
Period of validity:
Ongoing
Approval date:
2021
Revision date:
July 15, 2021
Changes date:
August 8, 2014
Year:
2025
Region / City:
Not specified
Subject:
Immune spatial transcriptomics, melanoma, immune cell analysis
Document Type:
Scientific figure description
Organization / Institution:
Not specified
Author:
Romano, G
Target Audience:
Researchers in immunology, oncology, and spatial transcriptomics
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Standard:
AABB 29th Standards 5.30
Thema:
Rh Immune Globulin prophylaxis
Dokumenttyp:
Transfusionsrichtlinie
Fachbereich:
Transfusionsmedizin
Betroffene Patientengruppe:
Rh negative Patientinnen und Patienten
Zielgruppe:
Schwangere Frauen und transfusionsmedizinische Dienste
Schwangerschaftszeitraum:
Pränatal, ≥20 Wochen Gestation, ≤20 Wochen Gestation, postpartal
Testverfahren:
ABO-Typisierung, Rh-Typisierung mit Weak D, Antikörpersuchtest, Fetalscreen Rosette-Test, Flow Cytometry Hemoglobin F, Kleihauer Betke Fetal Stain
Dosierung:
300 Mikrogramm Rh Immune Globulin pro Standarddosis
Berechnungsgrundlage:
Prozent fetaler Zellen × 50, Division durch 30 ml Vollblut pro Dosis
Indikation:
Exposition gegenüber Rh positiven Erythrozyten
Besondere Hinweise:
Fetalscreen nur gültig bei >20 Wochen und DAT negativem Neugeborenen
Year:
2023
Region / City:
Wuhan, China
Topic:
Immunology, Cancer Research, Gene Expression, Immunotherapy
Document Type:
Research Article
Institution:
Wuhan University of Science & Technology, Huazhong University of Science and Technology, Anhui Normal University
Authors:
Fei-Fei Hu, Chun-Jie Liu, Lan-Lan Liu, Qiong Zhang, An-Yuan Guo
Target Audience:
Researchers, Healthcare Professionals, Academics in Immunology and Oncology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Revision:
N/A
Year:
2023
Region / City:
Not specified
Topic:
Immunology, Cytotoxicity, Flow Cytometry
Document Type:
Research Supplementary Figures
Author:
Not specified
Target Audience:
Researchers, Immunologists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Los Angeles, CA, USA; Prague, Czech Republic; New Orleans, LA, USA; Birmingham, AL, USA; State College, PA, USA; Ithaca, NY, USA; Chengdu, China
Topic:
Extracellular Vesicles, Stem Cells, Immune Modulation, Diabetes Therapy
Document Type:
Research Supplementary Figures
Institution / Organization:
University of California, Los Angeles, University of California, Los Angeles, Tulane University, University of Alabama at Birmingham, Pennsylvania State University, Cornell University, Sichuan University
Author:
Jana Zarubova, Mohammad Mahdi Hasani-Sadrabadi, Yutong Wu, Graciel Diamante, Jenny Cheng, Xiao Han, Fatemeh Sadat Majedi, Li Yang, Olivia Wang, In Sook Ahn, Jianyi Zhang, Xiaojun Lance Lian, Zhen Gu, Manish J. Butte, Reza Ardehali, Peter C Butler, Tony Ye Hu, Louis-S. Bouchard, Xia Yang, Song Li
Target Audience:
Researchers in stem cell biology, regenerative medicine, diabetes therapy
Period of Effect:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Description:
Research supplementary material focusing on extracellular vesicles derived from pluripotent stem cells and their role in immune modulation for diabetes treatment, including experimental figures and lipid profiles.
Authors:
Jianhua Rao; Jiannan Qiu; Ming Ni; Hao Wang; Peng Wang; Lei Zhang; Zeng Wang; Mu Liu; Feng Cheng; Xuehao Wang; Ling Lu
Affiliations:
Hepatobiliary Center of The Affiliated Cancer Hospital (Jiangsu Cancer Hospital) and The First Affiliated Hospital, Nanjing Medical University; Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences; Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment; Collaborative Innovation Center for Personalized Cancer Medicine; State Key Laboratory of Reproductive Medicine
Institution:
Nanjing Medical University
Country:
China
Type of Document:
Supplementary Material
Discipline:
Immunology; Hepatology; Molecular Biology
Subject:
Role of macrophage Nrf2 deficiency and Timp3-mediated RhoA/ROCK pathway in ischemic liver injury
Experimental Models:
Mouse models; Bone marrow–derived macrophages (BMMs); Hepatic macrophages
Methods:
Cell isolation and culture; Biochemical measurements; Histopathology; Immunohistochemistry; Immunofluorescence; TUNEL staining; MDA, GSH and MPO assays; Western blotting; qRT-PCR; ELISA; RNA sequencing; Chromatin immunoprecipitation
Correspondence:
Ling Lu; Xuehao Wang; Feng Cheng
Equal Contribution:
Jianhua Rao; Jiannan Qiu; Ming Ni
Year:
2023
Region / City:
Queenstown, New Zealand
Topic:
Immune therapies, cancer treatment, cell and gene therapy
Document Type:
Event Description
Organization / Institution:
International Society for Cell and Gene Therapy (ISCT), Liger Leadership Academy
Authors:
Emily Blyth, Alicia Didsbury
Target Audience:
Researchers, medical professionals, general public interested in immune therapies
Date of Approval:
August 5, 2023
Date of Changes:
N/A
Program:
Medicare IVIG Demonstration
Administering Agency:
Centers for Medicare & Medicaid Services (CMS)
Country:
United States
Legal Basis:
Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012
Extended Under:
Disaster Tax Relief and Airport and Airway Extension Act of 2017
Further Extension:
Consolidated Appropriations Act, 2021
OMB Control Number:
0938-1246
CMS Form Number:
CMS-10518
Subject:
Application for beneficiary participation in the IVIG Demonstration
Target Population:
Medicare Part B beneficiaries with primary immune deficiency disease (PIDD)
Enrollment Cap:
6,500 beneficiaries (originally 4,000)
Funding Limit:
$45 million including administrative and evaluation costs
Coverage Scope:
Bundled payment for medically necessary supplies and services for in-home IVIG administration
Application Requirement:
Mandatory signed application by beneficiary and provider
Submission Methods:
Mail or fax
Languages Available:
English and Spanish
Period of Demonstration:
Through December 31, 2023 or until statutory limits are met
Participation Status:
Voluntary; may be terminated by beneficiary at any time
Institution:
Centrum Medische Genetica UZ Gent
Document type:
Clinical checklist
Subject:
Primary immune deficiency (PID) gene panel analysis
Legal reference:
Artikel 33, K.B. 10.11.2012 (in werking 1.1.2013)
Regulatory authority:
Recognized clinical geneticist validation requirement
Target group:
Referring physicians and clinical geneticists
Required information:
Patient identification, PID classification, clinical manifestations, screening results, familial history
Classification system:
International Union of Immunological Societies (IUIS) Expert Committee
Purpose:
Submission of clinical data for PID panel request validation
Fields included:
Patient name, date of birth, referring physician, RIZIV number, clinical indications, laboratory and genetic screening results